scholarly journals Home Monitoring Heart Failure Care Does Not Improve Patient Outcomes

Circulation ◽  
2012 ◽  
Vol 125 (6) ◽  
pp. 828-836 ◽  
Author(s):  
Akshay S. Desai
2018 ◽  
Vol 7 (4) ◽  
pp. 1 ◽  
Author(s):  
Leah M Raj ◽  
Leslie A Saxon ◽  
◽  

ICDs and resynchronisation devices are routinely implanted in patients with heart failure for primary prevention of sudden cardiac death or to treat the condition. The addition of device features and algorithms that directly or indirectly monitor cardiac haemodynamics to assess heart failure status can provide additional benefit by treating heart failure more continuously. Established and emerging devices and sensors aimed at treating or measuring cardiac haemodynamics represent the next era of heart failure disease management. Digitally enabled models of heart failure care, based on frequent haemodynamic measurements, will increasingly involve patients in their own disease management. Software tools and services tailored to provide patients with personalised information to guide diet, activity, medications and haemodynamic management offer an unprecedented opportunity to improve patient outcomes. This will enable physicians to care for larger populations because management will be exception based, automated and no longer depend on one-to-one patient and physician interactions.


2019 ◽  
Vol 35 (S1) ◽  
pp. 72-72
Author(s):  
Susan Myles ◽  
Ruth Louise Poole ◽  
Karen Facey

IntroductionEvidence supporting the use of pacemakers is well established. However, evidence about the optimal use of pacemaker telemonitoring for disease management in heart failure is not. Health Technology Wales (HTW) held a national adoption event to encourage implementation and best practice in use of pacemaker telemonitoring in the National Health Service (NHS) Wales to improve patient outcomes in heart failure.MethodsMulti-stakeholder national adoption workshop using a mixture of expert presentations, case studies and interdisciplinary group and panel discussions to agree key actions to understand the value and promote optimal use of pacemakers for remote disease monitoring in patients with heart failure in Wales.ResultsThe workshop was attended by forty-five senior professionals with an interest in improving care of patients with heart failure. Actions to progress included: providing a centralized Welsh system to support technical issues that arise with telemonitoring; considering interoperability with other NHS Wales systems; encouraging value-based procurement with collection of a core outcome set; agreeing implementation issues with both professionals and patients; audit to understand experience, resource use and outcomes; and sharing manufacturer evidence on the accuracy of telemanagement algorithms. It was suggested that these actions be progressed via an All-Wales multi-stakeholder approach, led by the Welsh Cardiac Network.ConclusionsDeveloping a more agile, lifecycle approach to technology appraisal is currently advocated; recalibrating the focus from technology assessment to technology management across the complete technology lifecycle. HTW will endeavour through regular adoption events to facilitate such a paradigm shift that aims to understand value and optimise use of evidence-based technologies.


2017 ◽  
Vol 17 (3) ◽  
pp. 141
Author(s):  
Rajiv Jayasena ◽  
Hang Ding ◽  
Alison Dowling ◽  
Gk Shridhar ◽  
Dean Richardson ◽  
...  

2020 ◽  
Vol 15 (SP1) ◽  
pp. 22-26
Author(s):  
Shiva Nandiwada ◽  
Justin Ezekowitz ◽  
Nawaf Al-Majed

Heart failure (HF) is increasing in prevalence and continues to have poor prognosis despite using up-to-date guideline-directed medical treatment and device intervention. There is a dire need for new therapies that can improve patient outcomes. New recently tested medical and interventional therapies have proven effective in reducing the morbidity, mortality and improving the quality of life for patients with HF and these therapies are discussed in details in this review. Ongoing large scale clinical trials are underway to determine the efficacy and safety of novel therapies of HF. Development of these medical and interventional therapies are improving our understanding of HF and paving the way to better clinical outcomes.


2012 ◽  
Vol 18 (8) ◽  
pp. S85
Author(s):  
Brian E. Jaski ◽  
Miriam Bender ◽  
Dale Glaser ◽  
Valorie Thomas ◽  
DeAnn S. Cary ◽  
...  

Author(s):  
Deepti Bhandare ◽  

Nearly 6.2 million people in the United states are affected by heart failure, it is predicted that this number will rise to 8.5 million by 2030 Significant effort has been made to prevent heart failure and its exacerbations. The Hospital Readmission Reduction Program (HRRP), a Medicaare based program, was established to link payment to quality of care. Payment is reduced to hospitals when patients are readmitted within 30 days for heart failure The “Heart Success Clinic” is an outpatient clinic started to improve patient outcomes and reduce readmission rates. Patients are provided with heart failure focused visits which includes detailed medication reviews, diet modification, weight loss, disease education, etc. During the six months prior to the opening of the clinic, the readmission rate was 15.27% at AdventHealth Sebring hospital which is a community-based hospital. Data was collected on the patients who attended the “Heart Success Clinic” for six months. Zero patients from the clinic were readmitted, bringing the readmission rate down from 15.27% to 0%. This pilot study gives promising initial results. Further studies can be conducted over a longer period time as to gather more patients. Overall, the study demonstrates that there is value in providing heart failure focused follow up visits in improving patient outcomes and readmission rates.


Sign in / Sign up

Export Citation Format

Share Document